印度最高法院允许Dr. Reddy's出口仿制司美格鲁肽，而诺和诺德的专利不适用。 India's top court allows Dr. Reddy’s to export generic semaglutide where Novo Nordisk’s patent doesn’t apply.

德里高等法院维持了下级法院的一项命令,允许雷迪博士的实验室制造和向诺沃·诺迪斯克缺乏专利保护的国家出口普通微粒,驳回了丹麦公司的上诉。 The Delhi High Court has upheld a lower court’s order allowing Dr. Reddy’s Laboratories to manufacture and export generic semaglutide to countries where Novo Nordisk lacks patent protection, rejecting the Danish company’s appeal. 法院认为Novo Nordisk的专利因缺乏创造性而易受损害, The court found Novo Nordisk’s patent vulnerable due to lack of inventiveness, citing prior scientific work and a broader patent covering GLP-1 molecules. 这项裁决在2026年3月20日印度专利到期前生效,允许只出口生产,并强调公共卫生准入,但鉴于即将到期的专利,Novo Nordisk不会立即受到伤害。 The ruling, effective before the Indian patent expires on March 20, 2026, permits export-only production and emphasizes public health access, with no immediate harm to Novo Nordisk given the impending patent expiry.